CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.

CureVac NV

Dr. Alexander  Zehnder M.B.A., M.D.

CEO, MD & Member of Management Board

Dr. Malte  Greune Ph.D.

COO, Member of Management Board & MD

Dr. Myriam  Mendila M.D.

Chief Scientific Officer, Head of R&D, MD & Member of the Management Board

Dr. Ulrike  Gnad-Vogt M.D., Ph.D.

Senior VP & Area Head of Oncology

Mr. Axel-Sven  Malkomes

CFO & Member of Executive Board

Mr. Thaminda  Ramanayake

Chief Business Officer & Member of Executive Board

Dr. Sarah  Fakih

Vice President Corporate Communications & Investor Relations

Mr. Marco  Rau L.L.M., Ph.D.

General Counsel

Mr. Thorsten  Schuller

Head of Corporate Communications

Slavica  Stevanovic-Heck

Head of Human Resources

CureVac NV (5CV) Stock Analysis, Discussion Forum and Financial Metrics - XETRA Exchange

CureVac NV (5CV) Earnings Report Date and History | XETRA

5CV's next earnings is on May 21, 2025 (After Market Close)

When is the earnings report for 5CV?

5CV Earnings History

5CV Stock Discussion Forum and Message Board

News for XETRA: 5CV